1. Indications and Usage
\nDiabetic Macular Edema (DME):
\nTreatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
\nNon-Infectious Posterior Uveitis:
\nTreatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Intravitreal Injection ONLY. Must be administered by an ophthalmologist.
\nRecommended Dosage:
\nDose: One implant (containing 0.19 mg or 0.18 mg depending on region\/version).
\nFrequency: Once every 3 years (36 months), as the implant is designed for continuous release over this period.
\nReadministration: If symptoms recur after 36 months, a second implant may be considered.
\nCritical Administration Instructions:
\nSterile Technique: Administer under sterile conditions with appropriate anesthesia and topical broad-spectrum bacteriostatic agent.
\nInjection Site: Typically injected into the vitreous cavity (e.g., 4 mm posterior to the limbus).
\n3. Mechanism of Action
\nCorticosteroid Activity:
\nFluocinolone acetonide is a potent synthetic glucocorticoid.
\nAnti-Inflammatory & Anti-Edema Effects:
\nIt inhibits the release of substances that sustain the inflammatory and edematous response. It stabilizes lysosomal membranes, reduces capillary permeability, and inhibits leukocyte migration and fibroblast proliferation.
\nTherapeutic Result: Reduces retinal edema and inflammation, thereby improving or stabilizing visual acuity.
\nSustained Release:
\nThe implant is a non-biodegradable micro-catheter that releases the drug at a constant low rate (e.g., ~0.2\u20130.5 \u00b5g\/day) directly into the vitreous.
\n4. Safety and Warnings
\nElevated Intraocular Pressure (IOP):
\nCorticosteroids may cause a clinically significant rise in IOP, which can lead to optic nerve damage and glaucoma.
\nAction: Monitor IOP at appropriate intervals.
\nCataract Formation:
\nProlonged use of corticosteroids may accelerate cataract formation (specifically posterior subcapsular cataracts).
\nEndophthalmitis:
\nAs with any intravitreal injection, there is a risk of intraocular infection (endophthalmitis).
\nContraindications:
\nActive or suspected ocular or periocular infections (e.g., viral keratitis).
\nPatients with glaucoma or IOP > 18 mmHg not controlled by medication.
\nHypersensitivity to the drug.
\n5.Adverse Reactions
\nMost Common:
\nCataract progression, elevated intraocular pressure, vitreous hemorrhage, vitreous floaters, and conjunctival hemorrhage.
\n6.Drug Interactions
\nNo Clinical Significance:
\nAs a locally acting protein\/steroid, systemic drug interactions are not expected. However, concomitant use with other ocular steroids increases the risk of IOP elevation.
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Fluocinolone Acetonide.
\nAppearance: Small, non-biodegradable, pre-loaded applicator.
\nStorage: Store below 25\u00b0C (77\u00b0F). Protect from light.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u4f18\u65bd\u83b9 \u00ae(Yutiq\u00ae)
\nGeneric Name: Fluocinolone Acetonide
\nStrength: 0.18 mg per implant, 1 implant per box
\nManufacturer: EyePoint Pharmaceuticals US, Inc.
\nMarketing Authorization Holder: OcuMension Therapeutics
\nApproval Date in China: June 16, 2022
\nRegistration Number: HJ20220056
\nStorage: Store sealed at temperature not exceeding 25\u00b0C, protect from light and moisture. Refer to the package insert for detailed storage specifications.<\/p>\n
Price&Cost:Contact Us now for the best price of Fluocinolone Acetonide(Yutiq\uff09<\/p>\n","protected":false},"featured_media":4175,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[68],"product_tag":[],"class_list":["post-4174","product","type-product","status-publish","has-post-thumbnail","product_cat-implant","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n